RedHill Biopharma Ltd. (RDHL)
USD 2.43
(-12.77%)
USD 2.43
(-12.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | -9.56 Million USD | -51.74% |
| 2022 | 71.3 Million USD | -39.31% |
| 2021 | 117.48 Million USD | 28.89% |
| 2020 | 91.15 Million USD | 92.98% |
| 2019 | 47.23 Million USD | 5.3% |
| 2018 | 44.85 Million USD | -16.71% |
| 2017 | 53.85 Million USD | 75.74% |
| 2016 | 30.64 Million USD | 39.26% |
| 2015 | 22 Million USD | 32.47% |
| 2014 | 16.61 Million USD | 54.03% |
| 2013 | 10.78 Million USD | 19.08% |
| 2012 | 9.05 Million USD | 14.69% |
| 2011 | 7.89 Million USD | 355.63% |
| 2010 | 1.73 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 5.39 Million USD | 119.92% |
| 2023 Q1 | -27.09 Million USD | -291.5% |
| 2023 FY | 34.41 Million USD | -51.74% |
| 2022 Q3 | 15.2 Million USD | -17.83% |
| 2022 Q1 | 23.44 Million USD | 0.02% |
| 2022 Q2 | 18.51 Million USD | -21.03% |
| 2022 FY | 71.3 Million USD | -39.31% |
| 2022 Q4 | 14.14 Million USD | -6.98% |
| 2021 Q2 | 35.79 Million USD | 25.72% |
| 2021 Q3 | 29.77 Million USD | -16.82% |
| 2021 Q4 | 23.43 Million USD | -21.3% |
| 2021 FY | 117.48 Million USD | 28.89% |
| 2021 Q1 | 28.47 Million USD | -6.69% |
| 2020 FY | 91.15 Million USD | 92.98% |
| 2020 Q1 | 16.35 Million USD | 30.17% |
| 2020 Q2 | 19.21 Million USD | 17.45% |
| 2020 Q3 | 25.06 Million USD | 30.48% |
| 2020 Q4 | 30.51 Million USD | 21.75% |
| 2019 Q3 | 10.61 Million USD | -21.47% |
| 2019 Q1 | 10.53 Million USD | -2.63% |
| 2019 Q2 | 13.51 Million USD | 28.34% |
| 2019 FY | 47.23 Million USD | 5.3% |
| 2019 Q4 | 12.56 Million USD | 18.37% |
| 2018 FY | 44.85 Million USD | -16.71% |
| 2018 Q4 | 10.81 Million USD | -4.64% |
| 2018 Q3 | 11.34 Million USD | 1.45% |
| 2018 Q2 | 11.18 Million USD | -2.85% |
| 2018 Q1 | 11.51 Million USD | -25.49% |
| 2017 Q3 | 14.55 Million USD | 5.84% |
| 2017 Q4 | 15.44 Million USD | 6.15% |
| 2017 FY | 53.85 Million USD | 75.74% |
| 2017 Q2 | 13.75 Million USD | 36.11% |
| 2017 Q1 | 10.1 Million USD | 11.11% |
| 2016 FY | 30.64 Million USD | 39.26% |
| 2016 Q4 | 9.09 Million USD | 7.55% |
| 2016 Q3 | 8.45 Million USD | 17.5% |
| 2016 Q2 | 7.19 Million USD | 21.89% |
| 2016 Q1 | 5.9 Million USD | -12.74% |
| 2015 Q1 | 4.75 Million USD | -1.23% |
| 2015 FY | 22 Million USD | 32.47% |
| 2015 Q4 | 6.76 Million USD | 47.29% |
| 2015 Q3 | 4.59 Million USD | -22.03% |
| 2015 Q2 | 5.89 Million USD | 23.86% |
| 2014 FY | 16.61 Million USD | 54.03% |
| 2014 Q4 | 4.81 Million USD | -3.99% |
| 2014 Q2 | 4.11 Million USD | 54.64% |
| 2014 Q1 | 2.66 Million USD | -23.5% |
| 2014 Q3 | 5.01 Million USD | 21.78% |
| 2013 FY | 10.78 Million USD | 19.08% |
| 2013 Q2 | 2.53 Million USD | 25.19% |
| 2013 Q1 | 2.02 Million USD | -4.62% |
| 2013 Q3 | 2.75 Million USD | 8.77% |
| 2013 Q4 | 3.48 Million USD | 26.49% |
| 2012 Q4 | 2.11 Million USD | 9.85% |
| 2012 Q1 | 2.93 Million USD | 19.29% |
| 2012 Q3 | 1.92 Million USD | -6.86% |
| 2012 Q2 | 2.07 Million USD | -29.49% |
| 2012 FY | 9.05 Million USD | 14.69% |
| 2011 FY | 7.89 Million USD | 355.63% |
| 2011 Q3 | 2.22 Million USD | 0.0% |
| 2011 Q4 | 2.46 Million USD | 10.55% |
| 2010 FY | 1.73 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | 215.851% |
| Alpha Teknova, Inc. | 45.85 Million USD | 120.849% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 104.878% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 121.316% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 106.005% |
| Cosmos Health Inc. | 26.18 Million USD | 136.519% |
| Journey Medical Corporation | 54.59 Million USD | 117.513% |
| Embecta Corp. | 528.4 Million USD | 101.809% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 103.516% |
| Dynavax Technologies Corporation | 219.14 Million USD | 104.363% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 101.62% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 102.929% |
| PainReform Ltd. | 9.58 Million USD | 199.76% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 172.849% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 172.849% |
| SCYNEXIS, Inc. | 51.84 Million USD | 118.44% |
| Safety Shot Inc | 12.1 Million USD | 178.953% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | 411.516% |
| Procaps Group, S.A. | 199.47 Million USD | 104.793% |
| Theratechnologies Inc. | 72.75 Million USD | 113.141% |
| Harrow Health, Inc. | 89.97 Million USD | 110.627% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | 201.217% |
| Biofrontera Inc. | 39.95 Million USD | 123.927% |
| DURECT Corporation | 43.71 Million USD | 121.871% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 101.807% |
| Cronos Group Inc. | 96.7 Million USD | 109.886% |
| OptiNose, Inc. | 85.1 Million USD | 111.235% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 104.119% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 124.42% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 103.044% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | 198.255% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 122.214% |
| Radius Health, Inc. | 265.92 Million USD | 103.595% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 169.073% |
| ProPhase Labs, Inc. | 37.85 Million USD | 125.259% |
| Phibro Animal Health Corporation | 260.29 Million USD | 103.673% |
| Procaps Group S.A. | 187.24 Million USD | 105.106% |
| Alvotech | 285.43 Million USD | 103.35% |
| TherapeuticsMD, Inc. | 9.82 Million USD | 197.313% |
| Viatris Inc. | 5.96 Billion USD | 100.16% |
| Rockwell Medical, Inc. | 15.37 Million USD | 162.189% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 115.978% |
| SIGA Technologies, Inc. | 22.04 Million USD | 143.374% |
| Tilray Brands, Inc. | 251.35 Million USD | 103.804% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 119.497% |
| Shineco, Inc. | 17.94 Million USD | 153.27% |
| PetIQ, Inc. | 192.72 Million USD | 104.961% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | 339.556% |
| Incannex Healthcare Limited | 30.05 Million USD | 131.814% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 100.599% |
| Alimera Sciences, Inc. | 62.64 Million USD | 115.263% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | 1353.915% |
| Assertio Holdings, Inc. | 368.58 Million USD | 102.594% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | 262.448% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 153.688% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 145.165% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 145.437% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 105.796% |
| Hempacco Co., Inc. | 7.59 Million USD | 225.861% |
| Talphera, Inc. | 11.99 Million USD | 179.715% |
| Alvotech | 285.43 Million USD | 103.35% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 106.795% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 102.772% |
| Currenc Group, Inc. | 24 Million USD | 139.834% |
| Kamada Ltd. | 45.42 Million USD | 121.047% |
| Indivior PLC | 911 Million USD | 101.05% |
| Evoke Pharma, Inc. | 12.4 Million USD | 177.045% |
| Flora Growth Corp. | 10.57 Million USD | 190.377% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 145.437% |
| Evolus, Inc. | 189.75 Million USD | 105.038% |
| HUTCHMED (China) Limited | 436.23 Million USD | 102.192% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 106.203% |
| Akanda Corp. | 3.48 Million USD | 374.465% |